These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20953652)

  • 41. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization.
    Furuno JP; Perencevich EN; Johnson JA; Wright MO; McGregor JC; Morris JG; Strauss SM; Roghman MC; Nemoy LL; Standiford HC; Hebden JN; Harris AD
    Emerg Infect Dis; 2005 Oct; 11(10):1539-44. PubMed ID: 16318693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Control of a hospital-wide vancomycin-resistant Enterococci outbreak.
    Kurup A; Chlebicki MP; Ling ML; Koh TH; Tan KY; Lee LC; Howe KB
    Am J Infect Control; 2008 Apr; 36(3):206-11. PubMed ID: 18371517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci.
    Leclercq R
    Clin Microbiol Infect; 2009 Mar; 15(3):224-31. PubMed ID: 19335370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Risk Factors, Costs, and Survival Analysis of Invasive VRE Infections at a Medical Center in Eastern Taiwan.
    Jiang HL; Zhou Z; Wang LS; Fang Y; Li YH; Chu CI
    Int J Infect Dis; 2017 Jan; 54():18-24. PubMed ID: 27836794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Vancomycin resistant enterococci in Austria].
    Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vancomycin-resistant enterococci.
    Rubinstein E; Keynan Y
    Crit Care Clin; 2013 Oct; 29(4):841-52. PubMed ID: 24094380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of Microbial Factors of Healthcare-Associated Infections Including Multidrug-Resistant Pathogens and Antibiotic Consumption at the University Intensive Care Unit in Poland in the Years 2011-2018.
    Litwin A; Fedorowicz O; Duszynska W
    Int J Environ Res Public Health; 2020 Sep; 17(19):. PubMed ID: 32977435
    [No Abstract]   [Full Text] [Related]  

  • 51. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.
    Nordmann P; Naas T; Fortineau N; Poirel L
    Curr Opin Microbiol; 2007 Oct; 10(5):436-40. PubMed ID: 17765004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
    Lam S; Singer C; Tucci V; Morthland VH; Pfaller MA; Isenberg HD
    Am J Infect Control; 1995 Jun; 23(3):170-80. PubMed ID: 7677262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection.
    Bates J
    J Hosp Infect; 1997 Oct; 37(2):89-101. PubMed ID: 9364258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial resistance of enterococci in Turkey.
    Kaçmaz B; Aksoy A
    Int J Antimicrob Agents; 2005 Jun; 25(6):535-8. PubMed ID: 15908184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of colonization and infection with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and of Clostridium difficile infection in Canadian hospitals.
    Simor AE; Williams V; McGeer A; Raboud J; Larios O; Weiss K; Hirji Z; Laing F; Moore C; Gravel D;
    Infect Control Hosp Epidemiol; 2013 Jul; 34(7):687-93. PubMed ID: 23739072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology and risk factors of methicillin-resistant
    Huang L; Zhang R; Hu Y; Zhou H; Cao J; Lv H; Chen S; Ding S; Chen G
    Antimicrob Resist Infect Control; 2019; 8():90. PubMed ID: 31164979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
    Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
    Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
    Entenza JM; Giddey M; Vouillamoz J; Moreillon P
    Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.